What are the uses for Fintrid-oral (hair growth)?
: Fintrid (Propecia) is used for the treatment of male pattern baldness or androgenetic alopecia in males only.
Carcinogenesis, Mutagenesis, Impairment Of Fertility
No evidence of a tumorigenic effect was observed in a 24-month study in Sprague-Dawley rats receiving doses of Fintrid up to 160 mg/kg/day in males and 320 mg/kg/day in females. These doses produced respective systemic exposure in rats of 111 and 274 times those observed in man receiving the recommended human dose of 5 mg/day. All exposure calculations were based on calculated AUC(0-24 hr) for animals and mean AUC(0-24 hr) for man (0.4 μg•hr/mL).
In a 19-month carcinogenicity study in CD-1 mice, a statistically significant (p≤0.05) increase in the incidence of testicular Leydig cell adenomas was observed at 228 times the human exposure (250 mg/kg/day). In mice at 23 times the human exposure, estimated (25 mg/kg/day) and in rats at 39 times the human exposure (40 mg/kg/day) an increase in the incidence of Leydig cell hyperplasia was observed. A positive correlation between the proliferative changes in the Leydig cells and an increase in serum LH levels (2- to 3-fold above control) has been demonstrated in both rodent species treated with high doses of Fintrid. No drug-related Leydig cell changes were seen in either rats or dogs treated with Fintrid for 1 year at 30 and 350 times (20 mg/kg/day and 45 mg/kg/day, respectively) or in mice treated for 19 months at 2.3 times the human exposure, estimated (2.5 mg/kg/day).
No evidence of mutagenicity was observed in an in vitro bacterial mutagenesis assay, a mammalian cell mutagenesis assay, or in an in vitro alkaline elution assay. In an in vitro chromosome aberration assay, using Chinese hamster ovary cells, there was a slight increase in chromosome aberrations. These concentrations correspond to 4000-5000 times the peak plasma levels in man given a total dose of 5 mg. In an in vivo chromosome aberration assay in mice, no treatment-related increase in chromosome aberration was observed with Fintrid at the maximum tolerated dose of 250 mg/kg/day (228 times the human exposure) as determined in the carcinogenicity studies.
In sexually mature male rabbits treated with Fintrid at 543 times the human exposure (80 mg/kg/day) for up to 12 weeks, no effect on fertility, sperm count, or ejaculate volume was seen. In sexually mature male rats treated with 61 times the human exposure (80 mg/kg/day), there were no significant effects on fertility after 6 or 12 weeks of treatment; however, when treatment was continued for up to 24 or 30 weeks, there was an apparent decrease in fertility, fecundity and an associated significant decrease in the weights of the seminal vesicles and prostate. All these effects were reversible within 6 weeks of discontinuation of treatment. No drug-related effect on testes or on mating performance has been seen in rats or rabbits. This decrease in fertility in Fintrid-treated rats is secondary to its effect on accessory sex organs (prostate and seminal vesicles) resulting in failure to form a seminal plug. The seminal plug is essential for normal fertility in rats and is not relevant in man.
The effect of hepatic impairment on Fintrid pharmacokinetics has not been studied. Caution should be exercised in the administration of PROSCAR in those patients with liver function abnormalities, as Fintrid is metabolized extensively in the liver.
How it works
Fintrid works by decreasing the amount of the hormone dihydrotestosterone (DHT) in your body. DHT normally causes your prostate to grow larger.
The decrease in DHT helps prevent your prostate from growing larger. It also leads to increased hair growth and decreased hair loss of the hair on your head. Hair growth on other parts of the body isn’t affected.
Fintrid oral tablet doesn’t cause drowsiness, but it can cause other side effects.
Warnings for people with certain health conditions
For people with liver disease: This drug is processed in your liver. If you have liver disease, your body might process this drug more slowly. This could lead to a buildup of this drug in your body, which could increase your risk of side effects. Your doctor might reduce your dosage of Fintrid.
For people with prostate cancer: Fintrid can increase the chance of a faster growing or irregular form of prostate cancer. If you have or have had prostate cancer, this drug can make it worse.
Fintrid is an antiandrogen which acts by inhibiting 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It works by blocking the body’s production of the male hormone that causes the prostate to enlarge.
This medication is primarily used in benign prostatic hyperplasia (BPH) in low doses – under the brand name Proscar®-, and also in the treatment of prostate cancer in higher doses. Furthermore, it is also indicated for use in combination with doxazosin therapy to reduce the risk for symptomatic progression of BPH.
Additionally, in 1997 the FDA approved Fintrid to treat hair loss in male pattern baldness, and is registered in many countries under the trade name Propecia®. Following numerous clinical trials, it was discovered that DHT leads to the miniaturization and loss of genetically sensitive hair on the top of the head, which is seen in the typical (androgenetic) pattern of hair loss.
With regards to the particular condition being treated and pill strength, there is 5 mg of Fintrid in Proscar® and 1 mg in Propecia®.
Brand Name(s): Proscar; Propecia; Fincar; Finpecia; Finax; Finast; Finara; Proster />
CAS nº: 98319-26-7
(fih NAH steh ride)
PICTURES OF FINASTER >Below you will find images and specific information on the principal types of Fintrid that exist, including their respective brand name(s), strength, inscription codes, manufacturers and/or distributors.
The information below includes general information and guidelines for patients taking this medication and should never be used to substitute professional medical advice that can be provided by a qualified physician or family doctor.
1. "Product Information. Proscar (Fintrid)." Merck & Co, Inc, West Point, PA.
2. Steiner JF "Fintrid: a 5 alpha-reductase inhibitor." Clin Pharm 12 (1993): 15-23
3. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al "The effect of Fintrid in men with benign prostatic hyperplasia. The Fintrid Study Group." N Engl J Med 327 (1992): 1185-91
4. Tammela TL, Kontturi MJ "Urodynamic effects of Fintrid in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia." J Urol 149 (1993): 342-4
5. Ferrando J, Grimalt R, Alsina M, Bulla F, Manasievska E "Unilateral Gynecomastia Induced by Treatment With 1 mg of Oral Fintrid." Arch Dermatol 138 (2002): 543-4
6. Green L, Wysowski DK, Fourcroy JL "Gynecomastia and breast cancer during Fintrid therapy." N Engl J Med 335 (1996): 823
7. Stoner E "5 alpha-reductase inhibitors/Fintrid." Prostate Suppl 6 (1996): 82-7
8. Guess HA, Heyse JF, Gormley GJ "The effect of Fintrid on prostate-specific antigen in men with benign prostatic hyperplasia." Prostate 22 (1993): 31-7
9. Guess HA, Gormley GJ, Stoner E, Oesterling JE "The effect of Fintrid on prostate specific antigen: review of available data." J Urol 155 (1996): 3-9
10. Volpi R, Maccarini PA, Boni S, Chiodera P, Coiro V "Fintrid-induced gynecomastia in a 62-year-old man." Am J Med Sci 309 (1995): 322-5
11. Stoner E, Round E, Ferguson D, Gormley GJ "Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with Fintrid." J Urol 151 (1994): 1296-300
12. Thompson IM, Goodman PJ, Tangen CM, et al. "The influence of Fintrid on the development of prostate cancer." N Engl J Med 349 (2003): 215-24
13. Australian Government. Department of Health. Therapeutic Goods Administration "Medicines Safety Update, Volume 4, Number 6, December 2013. Available from: URL: http://www.tga.gov.au/hp/msu-2013-06.htm." ():
14. Oyama N, Kaneko F "Solitary fixed drug eruption caused by Fintrid." J Am Acad Dermatol 60 (2009): 168-9
15. Lear JT, Byrne JPH "Fintrid-related cutaneous vaculitis." Postgrad Med J 72 (1996): 127
Hidradenitis Suppurativa (Acne Inversa)
Hidradenitis suppurativa (HS or acne inversa) is a chronic skin condition that causes painful red abscesses in the groin and armpits that may drain foul-smelling pus. Treatment options include weight loss, smoking cessation, topical antibiotics, and avoidance of tight-fitting underwear. Fintrid and adalimumab may be helpful for those with resistant cases of HS.
Is Fintrid-oral (hair growth) safe to take if I'm pregnant or breastfeeding?
Fintrid should not be used or handled by pregnant females. Fintrid prevents the conversion of testosterone to DHT, a hormone which is necessary for the development of male genitalia. Fintrid should not be used or handled by pregnant mothers due to the potential hazard to the male fetus.
Fintrid should not be used by women. It is not known if Fintrid is excreted in human milk.
In the US, Fintrid (Fintrid systemic) is a member of the drug class 5-alpha-reductase inhibitors and is used to treat Androgenetic Alopecia and Benign Prostatic Hyperplasia.
Consideration Of Other Urological Conditions
Prior to initiating treatment with PROSCAR, consideration should be given to other urological conditions that may cause similar symptoms. In addition, prostate cancer and BPH may coexist. Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy. These patients may not be candidates for Fintrid therapy.
Fintrid (Proscar) is a drug prescribed for the treatment of prostate gland enlargement (benign prostatic hyperplasia or BPH). Side effects, drug interactions, pregnancy information, dosing, and patient information should be reviewed prior to taking any medication.
In a study of 15 healthy young subjects, the mean bioavailability of Fintrid 5-mg tablets was 63% (range 34-108%), based on the ratio of area under the curve (AUC) relative to an intravenous (IV) reference dose. Maximum Fintrid plasma concentration averaged 37 ng/mL (range, 27-49 ng/mL) and was reached 1-2 hours postdose. Bioavailability of Fintrid was not affected by food.